| 1. | Fda today is issuing a public health adisory ( pha ) detailing the remoal of pergolide products from the market
Fda今天发布公共健康忠告，详细说明了培高利特撤市的情况。 |
| 2. | The remoal of pergolide products is not expected to adersely affect patient care because of the alternatie therapies aailable
培高利特的撤市希望对患者的治疗不会产生不利的影响，因为有其它的治疗药物可选择。 |
| 3. | Conclusions in this study , use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac - valve regurgitation
结论：研究发现使用多巴胺受体激动剂培高利特和卡麦角林可增加新发生的心脏瓣膜返流的风险。 |
| 4. | In light of this additional post - market safety information , the companies that manufacture and sell pergolide will stop shipping pergolide for distribution and , in cooperation with fda , will withdraw the products from the market
根据这一上市后安全信息，生产和销售该产品的公司将停止培高利特产品的流通，配合fda ，将市场上的产品召回。 |
| 5. | Patients treated with ergot derivatives who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades
在服用麦角?生物进行治疗的患者中，发生任何瓣膜3到4级返流的患者服用培高利特或卡麦角林的平均累积剂量显著高于瓣膜返流级别较低的患者。 |
| 6. | Results of 31 case patients with newly diagnosed cardiac - valve regurgitation , 6 were currently exposed to pergolide , 6 were currently exposed to cabergoline , and 19 had not been exposed to any dopamine agonist within the previous year
结果：有31例患者出现新诊断的心脏瓣膜返流，其中6例研究时正在服用培高利特， 6例使用卡麦角林，另外19例在研究的前一年中未再使用任何多巴胺受体激动剂。 |
| 7. | Conclusions the frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline , but not in patients taking non ? ergot - derived dopamine agonists , as compared with control subjects
结论：与对照组相比，服用培高利特或者卡麦角林的患者临床上发生重要瓣膜返流的频率显著增加，但服用非麦角?生的多巴胺受体激动剂的患者瓣膜返流的发生率却未增加。 |
| 8. | Background case reports and echocardiographic studies suggest that the ergot - derived dopamine agonists pergolide and cabergoline , used in the treatment of parkinson ' s disease and the restless legs syndrome , may increase the risk of cardiac - valve regurgitation
背景：病例报告和超声心动图研究提示，用于治疗帕金森病和不宁腿综合征的药物?麦角?生物，多巴胺受体激动剂培高利特和卡麦角林，可能增加发生心脏瓣膜返流的风险。 |
| 9. | Methods we performed an echocardiographic prevalence study in 155 patients taking dopamine agonists for parkinson ' s disease ( pergolide , 64 patients ; cabergoline , 49 ; and non ? ergot - derived dopamine agonists , 42 ) and 90 control subjects
方法：我们用超声心动图对155例正在服用多巴胺受体激动剂（ 64例服用培高利特， 49例服用卡麦角林， 42例服用非麦角?生的多巴胺受体激动剂）治疗帕金森病的患者和90例对照组进行了一项流行调查。 |
| 10. | Two recent new england journal of medicine studies confirm preious findings associating pergolide with increased chance of regurgitation ( backflow of blood ) of the mitral , tricuspid , and aortic ales of the heart . ale regurgitation is a condition in which ales don ' t close tightly , allowing blood to flow backward across the ale
《新英格兰医学杂志》最近的两篇文章证实了以前发现的有关培高利特增加心脏主动脉瓣、二尖瓣膜和三尖瓣血液回流可能性。 |
